Rigel Pharmaceuticals, Inc. (RIGL) compared with its closest peers (IRWD, XERS, HROW, LGND, MNKD): P/E 13.7 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Ironwood Pharmaceuticals, Xeris Biopharma, Harrow Health, Ligand Pharmaceuticals, MannKind, Atea Pharmaceuticals, Akebia Therapeutics, AnaptysBio, Arcutis Biotherapeutics and LifeVantage share Rigel Pharmaceuticals's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Harrow Health, Inc. (HROW) | $1.53B | -350.0 |
| Ligand Pharmaceuticals Incorporated (LGND) | $5.70B | 41.0 |
| MannKind Corporation (MNKD) | $1.33B | 283.0 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Akebia Therapeutics, Inc. (AKBA) | $243.63M | -80.3 |
| AnaptysBio, Inc. (ANAB) | $1.68B | -105.4 |
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | -223.4 |
| LifeVantage Corporation (LFVN) | $84.02M | 11.6 |
| Stock P/E | 13.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -36.9% |
| vs Industry | -20.1% |
RIGL overview · RIGL earnings · RIGL financials · RIGL KPIs · RIGL documents · RIGL ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.